Reading Time: 2 minutes
Veracyte (VCYT) is currently seen as an exciting turnaround story in the medical technology sector. Diagnostic companies often struggle to convert excellent scientific research into sustainable profitability. The report presented on May 5th for Q1 shows that Veracyte has not only reached this critical turning point but has significantly surpassed it. A 307% increase in net income is a strong message to the market. The adjusted EPS was also increased by about 68% to $0.52, while the consensus was only at $0.15. Additionally, the outlook for the current...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
